ResearcherChristian-Albrechts-Universität zu KielActive in the last 2 years
Anne‐Sophie Mehdorn
Matched on ORCID iD 0000-0003-4415-8371; OpenAlex author ID A5087806968. Sources: OpenAlex.
Their work
- Papers
- 5 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 19
2021: 1 paper · 2022: 1 paper · 2023: none · 2024: 1 paper · 2025: none · 2026: 2 papers
Papers 5
- Novel L1CAM-antibody drug conjugates exert potent anti-tumor activity in preclinical models of even advanced pancreatic cancer. First author DOI 10.1016/j.biopha.2026.119257↗
- L1CAMxCD3 bispecific antibodies exert potent anti-tumor effects in preclinical pancreatic cancer models considering the complex tumor stroma Co-author DOI 10.64898/2026.08.10.743835↗
- Epithelial and Mesenchymal-like Pancreatic Cancer Cells Exhibit Different Stem Cell Phenotypes Associated with Different Metastatic Propensities. Co-author DOI 10.3390/cancers16040686↗
- Biomarkers in Liquid Biopsies for Prediction of Early Liver Metastases in Pancreatic Cancer. Co-author DOI 10.3390/cancers14194605↗
- The Heterogeneity of the Tumor Microenvironment as Essential Determinant of Development, Progression and Therapy Response of Pancreatic Cancer. Co-author DOI 10.3390/cancers13194932↗
Closest collaborators
The 19 strongest of 19 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Susanne Sebens · 5 shared papers, 2021–2026 · strength 1.00
- Paper Novel L1CAM-antibody drug conjugates exert potent anti-tumor activity in preclinical models of even advanced pancreatic… DOI 10.1016/j.biopha.2026.119257↗
- Paper L1CAMxCD3 bispecific antibodies exert potent anti-tumor effects in preclinical pancreatic cancer models considering the… DOI 10.64898/2026.08.10.743835↗
- Paper The Heterogeneity of the Tumor Microenvironment as Essential Determinant of Development, Progression and Therapy Respon… DOI 10.3390/cancers13194932↗
- Anna Maxi Wandmacher · 3 shared papers, 2021–2026 · strength 0.69
- Paper Novel L1CAM-antibody drug conjugates exert potent anti-tumor activity in preclinical models of even advanced pancreatic… DOI 10.1016/j.biopha.2026.119257↗
- Paper L1CAMxCD3 bispecific antibodies exert potent anti-tumor effects in preclinical pancreatic cancer models considering the… DOI 10.64898/2026.08.10.743835↗
- Paper The Heterogeneity of the Tumor Microenvironment as Essential Determinant of Development, Progression and Therapy Respon… DOI 10.3390/cancers13194932↗
- Christoph Röcken · 3 shared papers, 2022–2026 · strength 0.60
- Paper Novel L1CAM-antibody drug conjugates exert potent anti-tumor activity in preclinical models of even advanced pancreatic… DOI 10.1016/j.biopha.2026.119257↗
- Paper L1CAMxCD3 bispecific antibodies exert potent anti-tumor effects in preclinical pancreatic cancer models considering the… DOI 10.64898/2026.08.10.743835↗
- Paper Biomarkers in Liquid Biopsies for Prediction of Early Liver Metastases in Pancreatic Cancer. DOI 10.3390/cancers14194605↗
- Daniela Wesch · 2 shared papers, 2026 · strength 0.47
- Paper Novel L1CAM-antibody drug conjugates exert potent anti-tumor activity in preclinical models of even advanced pancreatic… DOI 10.1016/j.biopha.2026.119257↗
- Paper L1CAMxCD3 bispecific antibodies exert potent anti-tumor effects in preclinical pancreatic cancer models considering the… DOI 10.64898/2026.08.10.743835↗
- Rüdiger Braun · 2 shared papers, 2026 · strength 0.47
- Paper Novel L1CAM-antibody drug conjugates exert potent anti-tumor activity in preclinical models of even advanced pancreatic… DOI 10.1016/j.biopha.2026.119257↗
- Paper L1CAMxCD3 bispecific antibodies exert potent anti-tumor effects in preclinical pancreatic cancer models considering the… DOI 10.64898/2026.08.10.743835↗
- Annika Bräuer · 2 shared papers, 2026 · strength 0.47
- Paper Novel L1CAM-antibody drug conjugates exert potent anti-tumor activity in preclinical models of even advanced pancreatic… DOI 10.1016/j.biopha.2026.119257↗
- Paper L1CAMxCD3 bispecific antibodies exert potent anti-tumor effects in preclinical pancreatic cancer models considering the… DOI 10.64898/2026.08.10.743835↗
- Jan-Paul Gundlach · 2 shared papers, 2024–2026 · strength 0.42
- Paper Novel L1CAM-antibody drug conjugates exert potent anti-tumor activity in preclinical models of even advanced pancreatic… DOI 10.1016/j.biopha.2026.119257↗
- Paper Epithelial and Mesenchymal-like Pancreatic Cancer Cells Exhibit Different Stem Cell Phenotypes Associated with Differen… DOI 10.3390/cancers16040686↗
- Tina Daunke · 2 shared papers, 2022–2026 · strength 0.36
- Silje Beckinger · 2 shared papers, 2022–2026 · strength 0.36
- Rainer Lothar Heuchel · 1 shared paper, 2026 · strength 0.24
- Benjamin Heckelmann · 1 shared paper, 2026 · strength 0.23
- Hendrike Knaack · 1 shared paper, 2024 · strength 0.18
- Lisa-Marie Philipp · 1 shared paper, 2024 · strength 0.18
- Udo Schumacher · 1 shared paper, 2024 · strength 0.18
- Yoshiaki Sunami · 1 shared paper, 2022 · strength 0.13
- Florian Bürtin · 1 shared paper, 2022 · strength 0.13
- Uwe A. Wittel · 1 shared paper, 2022 · strength 0.13
- Christoph Kahlert · 1 shared paper, 2022 · strength 0.13
- Faik Güntac Uzunoglu · 1 shared paper, 2022 · strength 0.13
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.